



---

**ENVIRONMENTAL MONITORS ALLY FOR SPEED ON BIO-THREAT ASSESSMENT;  
NEW COMBINED SYSTEM CUTS TIME FOR ACTION ON MONITORED THREATS --  
Innovative Biosensors, Inc. and BioVigilant Systems, Inc., Partner on  
Biological Detection & Warning Systems for Environmental Monitoring**

Rockville, MD and Tucson, AZ, January 14, 2008 – Two bio-monitoring technology companies have joined to speed rugged, portable bio-threat detectors for clients dependent on accurate, quick environmental assessments.

Innovative Biosensors, Inc. (IBI) of Rockville, MD, a company developing rapid, ultra-sensitive tests to identify harmful pathogens and BioVigilant Systems, Inc. of Tucson, AZ, a company delivering a family of optically based point monitoring solutions announced they will team to develop, manufacture and sell an integrated biological threat identification system for implementation in biosafety environments.

Under the agreement, BioVigilant will provide integration services, as well as its biological detector capabilities, while IBI will provide the collection and identifier components via their "BioFlash" platform.

IBI's proprietary BioFlash biological identifier is rugged, portable, and incorporates a high-volume aerosol sampler. The well integrated technology provides rapid, specific and sensitive identification of up to 21 biological threat agents in single test or multi-test formats in less than five minutes.

"IBI's BioFlash has, for the first time, integrated the processes of collection and real-time identification; and this collaboration will allow our customers to further exploit its unique capabilities", said Scott McGill, BioVigilant's Vice President, Security Business Unit.

BioVigilant's patented point trigger solution provides real-time, high sensitivity, 24/7 bio-monitoring for a range of environments including clean rooms and indoor facilities, as well as challenging outdoor deployments. BioVigilant's patented "particle by particle" assessment method allows its end users to fully assess a given environment or threat condition.

"The technology platform being developed by BioVigilant has the potential for significantly enhancing the processes that commercial, government and military organizations use to monitor and control environments," said Rick Thomas, Vice President of Business Development for IBI. "Furthermore, the ability to provide results continuously and in real-time is critical to cost effective and rapid warning to meet the needs of clients."

**About Innovative Biosensors, Inc.**

Innovative Biosensors, Inc. is a privately held company developing novel technologies for the rapid detection of pathogens in biodefense applications and human clinical diagnostics. IBI's technology has been tailored to rapidly and sensitively detect biological threats in building security, military, and civil defense applications. Additionally, the technology platform is being used to develop rapid tests for the detection of hospital-acquired infections. Additional information is available at [Innovative Biosensors, Inc. \(IBI\)](http://www.innovativebiosensors.com).

**About BioVigilant Systems, Inc.**

BioVigilant develops, builds and maintains a family of environmental monitoring instruments for use in pharmaceutical manufacturing, military, security, and other applications. Through the novel use of Instantaneous Microbial Detection technology, BioVigilant's scientists have created instruments with entirely new classes of functionality and unparalleled sensitivity and accuracy than had been possible using existing methodology. BioVigilant, based in Tucson, AZ, maintains development operations in Austin, TX and Boston, MA. [BioVigilant Systems](http://www.biovigilant.com)

This release may contain forward-looking statements that are subject to certain risks and uncertainties, including Innovative Biosensors, Inc.'s mission to develop and commercialize instrument systems, Innovative Biosensors, Inc.'s ability to develop new technologies to conduct rapid diagnosis. Such statements are based on management's current expectations and are subject to a

number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Innovative Biosensors, Inc. cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: Innovative Biosensors, Inc.'s expectations that they will incur operating losses in the near future, the early stage of preclinical and clinical testing and trials, uncertainties surrounding the availability of additional funding, Innovative Biosensors, Inc.'s reliance on research collaborations, the actions of competitors and the development of competing technologies, potential patent infringement claims against Innovative Biosensors, Inc.'s products, processes and technologies, Innovative Biosensors, Inc.'s ability to protect their patents and proprietary rights and uncertainties relating to commercialization rights.

This release may contain certain "forward-looking statements," which are all statements made by or on behalf of BioVigilant Systems, Inc. that relate to its projections of revenues, earnings, income, losses, capital expenditures, dividends, capital structure or other future items, plans and objectives for future operations, products or services, future economic performance, and any assumptions underlying or relating to the foregoing. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "will," "expect," "intend," "estimate," "forecast," "anticipate," "believe," "project," "should," "plan," or "continue," or the negative thereof or variations thereon or similar terminology. Although BioVigilant Systems, Inc. believes that the expectations reflected in the forward-looking statements are reasonable, no assurance can be given that such expectations will prove to be accurate. BioVigilant Systems, Inc.'s business and operations are subject to substantial risks that increase the uncertainties inherent in the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements ("cautionary statements") include, without limitation, any shortfall in financing BioVigilant Systems, Inc.'s operations, current and future losses, any difficulties with suppliers, joint development partners or research collaborations, any delay or failure to obtain FDA or other governmental approvals, competition, changes in the product markets, any claims of infringement upon the intellectual property rights of others, and any inability to adequately protect intellectual property or other proprietary rights. All written and oral forward-looking statements attributable to BioVigilant Systems, Inc. or persons acting on its behalf, are qualified in their entirety by the cautionary statements. The inclusion of forward-looking statements should not be regarded as a representation that the future events, plans or expectations, financial projections and performance or acceptance of BioVigilant Systems, Inc.'s products and services in the marketplace will be achieved. BioVigilant Systems, Inc. disclaims any obligation to subsequently revise forward-looking statements to reflect any change in its expectations or the occurrence of unanticipated events.

General Contact:

**Innovative Biosensors, Inc.**

**Joe Hernandez**

President & Chief Executive Officer

Phone: 301.517.0324

[info@innovativebiosensors.com](mailto:info@innovativebiosensors.com)

**Richard Thomas**

Vice President of Business Development

Phone: 410.638.1144

[info@innovativebiosensors.com](mailto:info@innovativebiosensors.com)

**BioVigilant Systems, Inc.**

**Deward F. Manzer**

President & Chief Executive Officer

Phone: 520.498.0427

[dmanzer@biovigilant.com](mailto:dmanzer@biovigilant.com)

**Scott McGill**

Vice President, Security Business Unit

Phone: 512.565.8508

[smcgill@biovigilant.com](mailto:smcgill@biovigilant.com)

Media Contact Only:

**Joanne Stephenson**

Innovative Biosensors, Inc.

Head of Strategic Marketing

Phone: 301-738-0723

[jstephenson@innovativebiosensors.com](mailto:jstephenson@innovativebiosensors.com)

**Mike Munday**

BioVigilant Systems, Inc.

Corporate Development

Phone: 520-991-9591

[mmunday@biovigilant.com](mailto:mmunday@biovigilant.com)

